A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 03 Feb 2017
At a glance
- Drugs Antrodia cinnamomea (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Oneness Biotech
- 03 Feb 2017 Last checked against ClinicalTrials.gov record.
- 25 Jan 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 25 Jan 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.